COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,557 Articles (22,400 medRxiv, 8,157 bioRxiv)

Most recent first Previous |  Page 660: Articles 6591-6600  | Next

SARS-CoV-2 breakthrough infection during the Delta-dominant epidemic and neutralizing antibodies against Omicron in comparison with the third dose of BNT162b2: a matched analysis
Yamamoto, S., Matsuda, K., Maeda, K., Oshiro, Y., Inamura, N., Mizoue, T., Konishi, M., TAKEUCHI, J. S., Horii, K., Ozeki, M., Sugiyama, H., Mitsuya, H., Sugiura, W., Ohmagari, N.
10.1101/2022.06.21.22276682 — Posted: 2022-06-23
OpenSAFELY: Representativeness of Electronic Health Record platform OpenSAFELY-TPP data compared to the population of England.
The OpenSAFELY Collaborative, , Andrews, C. D., Schultze, A., Curtis, H. J., Hulme, W. J., Tazare, J., Evans, S. J., Mehrkar, A., Bacon, S. C., Hickman, G., Bates, C., Parry, J., Hester, F., Harper, S., Cockburn, J., Evans, D., Ward, T., Davy, S., Inglesby, P., Goldacre, B., MacKenna, B., Tomlinson, L. A., Walker, A. J.
10.1101/2022.06.23.22276802 — Posted: 2022-06-23
S373P Mutation of Spike Protein in SARS-CoV-2 Stabilizes Omicron
Zheng, B., Xiao, Y., Tong, B., Mao, Y., Ge, R., Tian, F., Dong, X., Zheng, P.
10.1101/2022.06.22.497114 — Posted: 2022-06-23
COVID-19 vaccine booster strategies in light of emerging viral variants: Frequency, timing, and target groups
Kelly, S. L., Le Rutte, E., Richter, M., Penny, M. A., Shattock, A. J.
10.1101/2022.06.22.22276760 — Posted: 2022-06-23
A Multi-Institutional Study Benchmarking Cycle Threshold Values for Major Clinical SARS-CoV-2 RT-PCR Assays
Kirby, J. E., Cheng, A., Cleveland, M. H., Degli-Angeli, E., DeMarco, C. T., Faron, M., Gallagher, T. L., Garlick, R. K., Goecker, E., Coombs, R. W., Huang, C., Louzao, R., Denny, T. N., Morreale, E., Oakley, G., Reymann, G., Schade, A., Scianna, S., Tsongalis, G. J., Vallone, P. M., Huggett, J., Ledeboer, N. A., Lefferts, J. A.
10.1101/2022.06.22.22276072 — Posted: 2022-06-23
Receipt of anti-SARS-CoV-2 pharmacotherapies among U.S. Veterans with mild to moderate COVID-19, January-February 2022
Bajema, K. L., Wang, X. Q., Hynes, D. M., Rowneki, M., Hickok, A., Cunningham, F., Bohnert, A., Boyko, E. J., Iwashyna, T. J., Maciejewski, M. L., Viglianti, E. M., Streja, E., Yan, L., Aslan, M., Huang, G. D., Ioannou, G. N.
10.1101/2022.06.22.22276782 — Posted: 2022-06-23
Improved SARS-CoV-2 neutralization of Delta and Omicron variants of concern after fourth vaccination in hemodialysis patients
Cheng, C.-C., Platen, L., Christa, C., Tellenbach, M., Kappler, V., Bester, R., Liao, B.-H., Holzmannn-Littig, C., Werz, M., Schoenhals, E., Platen, E., Eggerer, P., Treguer, L., Kuechle, C., Schmaderer, C., Heemann, U., Renders, L., Protzer, U., Braunisch, M. C.
10.1101/2022.06.22.22276787 — Posted: 2022-06-23
Genetic risk factors associated with SARS-CoV-2 susceptibility in multiethnic populations
Sriram, A.
10.1101/2022.06.23.22276797 — Posted: 2022-06-23
New, fast, and precise method of COVID-19 detection in nasopharyngeal and tracheal aspirate samples combining optical spectroscopy and machine learning
Ceccon, D. M., Amaral, P. H. R., Andrade, L. M., da Silva, M. I. N., Andrade, L. A. F., Moraes, T. F. S., Bagno, F. F., Rocha, R. P., de Almeida Marques, D. P., Ferreira, G. M., Lourenco, A. A., Ribeiro, A. L., Coelho-dos-Reis, J. G. A., da Fonseca, F. G., Gonzalez, J. C.
10.1101/2022.06.22.22276755 — Posted: 2022-06-23
Immune Correlates Analysis of the PREVENT-19 COVID-19 Vaccine Efficacy Clinical Trial
Fong, Y., Huang, Y., Benkeser, D., Carpp, L. N., Anez, G., Woo, W., McGarry, A., Dunkle, L. M., Cho, I., Houchens, C. R., Martins, K., Jayashankar, L., Castellino, F., Petropoulos, C., Leith, A., Haugaard, D., Webb, B., Lu, Y., Yu, C., Borate, B., van der Laan, L. W. P., Hejazi, N. S., Randhawa, A. K., Andrasik, M. P., Kublin, J. G., Hutter, J., Keshtkar-Jahromi, M., Beresnev, T. H., Corey, L., Neuzil, K. M., Follmann, D., Ake, J. A., Gay, C. L., Kotloff, K. L., Koup, R. A., Donis, R. O., Gilbert, P. B., Immune Assays Team, , Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team, , United States Government (USG)/CoVPN Biostatistics Team
10.1101/2022.06.22.22276362 — Posted: 2022-06-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).